References
- Society AC. Cancer facts & figures 2018. Atlanta: American Cancer Society; 2018 [cited 2019 Jul–Aug 19]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.
- SEER stat fact sheets: chronic lymphocytic leukemia (CLL); 2019 [cited 2019 Jul–Aug 19]. Available from: http://seer.cancer.gov/statfacts/html/clyl.html.
- Kabadi SM, Goyal RK, Nagar SP, et al. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803–3810.
- Frey S, Blankart CR, Stargardt T. Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature. Pharmacoeconomics. 2016;34(5):479–498.
- Nabhan C, Chung J, Mato AR, et al. Comparison of costs and health care resource utilization (HRU) in chronic lymphocytic leukemia (CLL) patients treated with front-line ibrutinib or chemoimmunotherapy. Blood. 2018;132(Supplement 1):4758– 2111.
- Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946–965.
- IMBRUVICA. IMBRUVICA (ibrutinib) prescribing information (Revised May 2016). Sunnyvale, CA: Pharmacyclics; 2016.
- TREANDA. TREANDA (bendamustine hydrochloride) prescribing information (Revised March 2015). North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2015.
- Zelenetz AD, Gordon LI, Wierda WG, National Comprehension Cancer Network, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015;13(3):326–362.
- Zelenetz AD, Gordon LI, Wierda WG, et al. Non-hodgkin's lymphomas, version 4. J Natl Compr Canc Netw. 2014;12(9):1282–1303.
- RITUXAN. RITUXAN (rituximab) prescribing information (Revised April 2016). South San Francisco, CA: Genentech; 2016.
- Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German chronic lymphocytic leukemia study group. J Clin Oncol. 2012;30(26):3209–3216.
- O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58.
- Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–1267.